Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | F12 | P00748 | 6/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16762181 | 0.88 | ALDH1A1 (0.43) | POLBTDP1FOLH1KMT2AALDH1A1 | |
| SCHEMBL16762209 | 0.88 | TSHR (0.51) | POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6123084 | 0.87 | POLB (0.38) | TRPM8POLBTDP1NPY5RFOLH1 | |
| SCHEMBL16762195 | 0.87 | HDAC6 (0.45) | TRPM8POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29964087 | 0.86 | CTSK (0.50) | TRPM8ALDH1A1 | |
| SCHEMBL21715248 | 0.86 | CTSK (0.50) | TRPM8ALDH1A1 | |
| SCHEMBL16762027 | 0.85 | FOLH1 (0.43) | TRPM8POLBTDP1FOLH1KMT2A | |
| SCHEMBL16762178 | 0.83 | ALDH1A1 (0.46) | TRPM8POLBTDP1ALDH1A1USP2 | |
| SCHEMBL16762075 | 0.83 | ALDH1A1 (0.46) | TRPM8POLBTDP1ALDH1A1USP2 | |
| SCHEMBL16762032 | 0.83 | POLB (0.46) | TRPM8POLBTDP1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | 7 Hills Pharma LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | 7 HILLS PHARMA INC. | 2021-05-20 | — | — | US | disclosed |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10342866-B2 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | 7 HILLS INTERESTS LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3388429-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2881393-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2881392-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2640721-B1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2017-02-16 | — | — | US | disclosed |
| US-20160339098-A1 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | 7 HILLS PHARMA INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160000755-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS PHARMA INC. | 2016-01-07 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| EP-2881393-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | TRPM8 559/4885POLB 4149/4885TDP1 4720/4885 |
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | CD47, ITGB1, ITGAM | TRPM8 1048/4885POLB 3036/4885TDP1 4306/4885 |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TRPM8 639/4885POLB 4239/4885TDP1 4768/4885 |
| US-20160000755-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | ITGB7, ITGB1, ITGA1 | TRPM8 1967/4885POLB 3794/4885TDP1 4383/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | TRPM8 520/4885POLB 4210/4885TDP1 4738/4885 |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TRPM8 520/4885POLB 4210/4885TDP1 4738/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TRPM8 559/4885POLB 4149/4885TDP1 4720/4885 |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | ITGB7, ITGA1, ITGAL | TRPM8 1132/4885POLB 3578/4885TDP1 4406/4885 |
| US-10342866-B2 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | CD4, ICOS, CD274 | TRPM8 1125/4885POLB 2152/4885TDP1 3130/4885 |
| US-20160339098-A1 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | CD4, CD274, ICOS | TRPM8 1099/4885POLB 2358/4885TDP1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.